Basking Ridge, NJ, United States of America

Per A Peterson

This inventor holds 34 USPTO granted patents and 1 published patent application, plus 4 CIPO patents and 4 EPO patents, primarily in Cancer Immunotherapy. Top assignees: Scripps Research Institute, Ortho-Mcneil Pharmaceutical Corp., Janssen Pharmaceuticals, Inc.. Active years: 1994-2015.

USPTO Granted Patents = 34 

% Patents Active = 58.8


 

Average Co-Inventor Count = 4.5

ph-index = 13

Forward Citations = 307(Granted Patents)


Location History:

  • LaJolla, CA (US) (1994 - 1999)
  • Bedminster, NJ (US) (2000 - 2001)
  • Bedminister, NJ (US) (2001)
  • Sante Fe, CA (US) (2006)
  • Rancho Santa Fe, CA (US) (2001 - 2011)
  • Rancho Sante Fe, CA (US) (1999 - 2015)
  • Basking Ridge, NJ (US) (2010 - 2015)

Company Filing History:


Years Active: 1994-2015

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Cell Therapy
Cytotoxic T Lymphocytes
Antigen Presenting Systems
MHC Class II
Cancer Treatment
Transgenic Mice
In Vitro Activation
Synthetic Antigens
Tumor Treatment
Autoimmune Disease
Allergic Disease
34 patents (USPTO):Explore Patents

I'm delighted to explore the incredible journey of inventor Per A Peterson, whose passion for innovation and relentless pursuit of excellence continue to inspire the next generation of inventors and shape the future of technology. Per A Peterson, based in Basking Ridge, NJ (US), has accumulated an impressive 34 patents, showcasing his remarkable ingenuity and dedication to pushing the boundaries of science and technology. His latest patent revolves around a groundbreaking cell therapy method for the treatment of tumors, addressing the challenge of diminished T cell responses in individuals with compromised immune systems.

Latest Patents:

Per A Peterson's cell therapy method involves isolating, stimulating, and expanding naive cytotoxic T lymphocyte precursors (CTLp) to antigen-specific effectors capable of effectively targeting and destroying tumor cells in vivo. By utilizing artificial antigen presenting cells (AAPCs) transfected with human HLA class I and specific accessory molecules, a robust and reproducible generation of polyclonal responses against tumor cells expressing specific peptides is achieved. This innovative approach holds immense potential for treating a wide range of cancers in a significant portion of the population.

Career Highlights:

Throughout his illustrious career, Per A Peterson has made significant contributions to the field of biotechnology and pharmacology. Notable stints at renowned institutions such as The Scripps Research Institute and Ortho-McNeil Pharmaceutical Corp have further solidified his reputation as a visionary inventor shaping the landscape of modern medicine.

Collaborations:

Collaborating with esteemed colleagues such as Michael R Jackson and Zeling Cai, Per A Peterson has harnessed the power of teamwork to drive innovation and bring transformative ideas to fruition. These collaborations have not only enriched his own work but have also facilitated the exchange of knowledge and expertise within the scientific community.

In conclusion, Per A Peterson's remarkable journey as an inventor epitomizes the spirit of innovation and serves as a beacon of inspiration for aspiring inventors worldwide. His pioneering contributions to the field of biotechnology underscore the transformative impact of dedicated individuals in shaping the future of technology and healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…